Nonspecific cellular accumulation of 99mTc-labeled oligonucleotides in culture is influenced by their guanine content

Nuclear Medicine and Biology

Volumn 34, Issue 1, 2007, Pages 47-54

  Wang, Yi ^a   Liu, Xinrong ^a   Zhang, Yumin ^b   Liu, Guozheng ^a   Rusckowski, Mary ^a   Hnatowich, Donald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Antisense imaging; Guanine; Nonspecific cell accumulation; Oligonucleotide; Technetium 99m

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; GUANINE; MESSENGER RNA; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; PHOSPHOROTHIOIC ACID DERIVATIVE; POLYADENYLIC ACID; POLYCYTIDYLIC ACID; POLYGLYCYLGLYCYLGLYCYLALANINE PHOSPHOROTHIOATE OLIGONUCLEOTIDE; POLYTHYMIDYLIC ACID; TECHNETIUM 99M; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CELL TYPE; CONTROLLED STUDY; DNA BASE COMPOSITION; DRUG ACCUMULATION; DRUG TARGETING; HUMAN; HUMAN CELL; ISOTOPE LABELING; PROTEIN CONTENT;

BREAST NEOPLASMS; CELL LINE, TUMOR; GUANINE; HUMANS; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; OLIGONUCLEOTIDES; RADIOPHARMACEUTICALS; TECHNETIUM;

EID: 33845950367     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.10.007     Document Type: Article

References (21)

1. Hnatowich D.J. Antisense and nuclear medicine. J Nucl Med 40 (1999) 693-703
2. Nakamura K., Kubo A., and Hnatowich D.J. Antisense targeting of P-glycoprotein expression in tissue culture. J Nucl Med 46 (2005) 509-513
3. 99mTc-labeled antisense DNA. J Nucl Med 42 (2001) 1660-1669
4. Nakamura K., Fan C., Liu G., Gupta S., He J., Dou S., et al. Evidence of antisense tumor targeting in mice. Bioconjug Chem 15 (2004) 1475-1480
5. Ambrosini G., Adida C., and Altieri D.C. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
6. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., and Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6 (2000) 127-134
7. Monzó M., Rosell R., Felip E., Astudillo J., Sánchez J.J., Maestre J., et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17 (1999) 2100-2104
8. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., and Tanigawa N. Inhibition of apoptosis by surviving predicts shorter survival rates in colorectal cancer. Cancer Res 58 (1998) 5071-5074
9. Yoshida H., Ishiko O., Sumi T., Matsumoto Y., and Ogita S. Survivin, Bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol 19 (2001) 537-542
10. Grossman D., Mcniff J.M., Li F., and Altieri D.C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113 (1999) 1076-1081
11. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (2003) 46-54
12. Olie R.A., Simões-Wüst A.P., Baumann B., Leech S.H., Fabbro D., Stahel R.A., et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60 (2000) 2805-2809
13. Xia C., Xu Z., Yuan X., Uematsu K., You K., Li K., et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1 (2002) 687-694
14. Li F., Ackermann E.J., Bennett C.F., Rothermel A.L., Plescia J., Tognin S., et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1 (1999) 461-466
15. Chen J., Wu W., Tahir S.K., Kroeger P.E., Rosenberg S.H., Cowsert L.M., et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2 (2000) 235-241
16. Winnard P., Chang F., Rusckowski M., Mardirossian G., and Hnatowich D.J. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl Med Biol 24 (1997) 425-432
17. Liu G., Zhang S., He J., Zhu Z., Rusckowski M., and Hnatowich D.J. Improving the labeling of S-acetyl NHS-MAG3 conjugated morpholino oligomers. Bioconjug Chem 13 (2002) 893-897
18. Mardirossian G., Lei K., Rusckowski M., Chang F., Qu T., Egholm M., et al. In vivo hybridization of technetium-99m-labeled peptide nucleic acid (PNA). J Nucl Med 38 (1997) 907-913
19. Hnatowich D.J., Mardirossian G., Fogarasi M., Sano T., Smith C.L., Cantor C.R., et al. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice. J Pharmacol Exp Ther 276 (1996) 326-334
20. Zhang Y., Liu N., Zhu Z., Rusckowski M., and Hnatowich D.J. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur J Nucl Med Mol Imaging 27 (2000) 1700-1707
21. Liu X., Nakamura K., Wang Y., Wang Y., Liu G., He J., et al. Initial mechanistic studies of antisense targeting in cells. J Nucl Med 47 (2006) 360-368